| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.02 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.02 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.02 |